A new study published in the journal Scientific Reports found that testing for a specific immune biomarker allows clinicians to identify whether growths on the ovaries are cancerous or not without the need for tests like the MRI scans or ultrasounds. Ovarian cancer is one of the most common gynaecologic cancers with the highest mortality rate. About 300000 new cases are diagnosed globally each year with an estimated 60 per cent of women dying within five years after diagnosis. Our new test is as accurate as the combined results of a standard blood test and ultrasound. This is especially important
